A trade group representing large compounding pharmacies sued the FDA over its removal of a widely prescribed Lilly diabetes ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Further dampening sentiment on Monday was an order from a U.S. judge for market heavyweight Alphabet's Google to overhaul its ...

Activist investor Starboard Value has reportedly taken a $1 billion stake in Pfizer in an attempt to turn the pharma’s ...